Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.
Köstler, W J
Granit, R Z
Nair, H B
Hennessy, B T
Gonzalez-Angulo, A M
Tekmal, R R
Mills, G B
AffiliationDepartment of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.
Carcinoma, Intraductal, Noninfiltrating
Epidermal Growth Factor
Gene Expression Profiling
Green Fluorescent Proteins
Mammary Glands, Human
Oligonucleotide Array Sequence Analysis
Reverse Transcriptase Polymerase Chain Reaction
MetadataShow full item record
CitationModeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. 2012, 31 (7):907-17 Oncogene
AbstractA large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.
- Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
- Authors: Shekhar MP, Kato I, Nangia-Makker P, Tait L
- Issue date: 2013 Feb
- Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
- Authors: Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, Dering J, Reedijk M
- Issue date: 2010 Aug
- Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
- Authors: Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F
- Issue date: 2014 Feb
- Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
- Authors: Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
- Issue date: 2012 Aug 2
- Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
- Authors: Horimoto Y, Terao T, Tsutsumi Y, Tanabe M, Mogushi K, Hlaing MT, Sasaki R, Saeki H, Okazaki M, Sonoue H, Arakawa A, Saito M
- Issue date: 2019 Sep